

**BEST AVAILABLE COPY****AMENDMENTS****In the claims:**

16. (Currently Amended) A method of inhibiting a binding event between a first-target protein (T) and a ~~second~~-binding protein (P) in a host, said method comprising:

administering to said host an effective amount of a non-naturally occurring bifunctional inhibitor molecule (I) of less than 5000 daltons consisting essentially of:

- (a) a target protein ligand that specifically binds to a said first target protein (T); and
- (b) a blocking protein ligand that specifically binds to a blocking protein (B) ,

wherein said target protein ligand and said blocking protein ligand are covalently bonded to each other, optionally through a linking group;

in order to simultaneously non-covalently bind said first the target protein (T) and the said blocking protein (B) to produce a tripartite complex (T-I-B) that inhibits said binding event of said second-binding protein to said first-target-protein prevents access of the binding protein (P) to the target protein (T).

17. (Original) The method according to Claim 16, wherein said bifunctional inhibitor molecule comprises a linking group.

18. (Currently Amended) The method according to Claim 16, wherein said bifunctional inhibitor molecule (I) binds to a site of said target protein that is also bound by said ~~second~~-binding protein (P).

**BEST AVAILABLE COPY**

19. (Currently Amended) The method according to Claim 16, wherein said bifunctional inhibitor molecule (I) binds to a site of said target protein (T) that is not bound by said ~~second~~ binding protein (P).
20. (Original) The method according to Claim 16, wherein said tripartite complex is produced intracellularly.
21. (Original) The method according to Claim 16, wherein said tripartite complex is produced extracellularly.
22. (Currently Amended) The method according to Claim 16, wherein said blocking protein (B) is endogenous to said host.
23. (Currently Amended) The method according to Claim 22, wherein said blocking protein (B) is selected from the group consisting of: peptidyl-prolyl isomerases, Hsp90 (Heat shock protein 90), steroid hormone receptors, cytoskeletal proteins, albumin and vitamin receptors.
24. (Currently Amended) The method according to Claim 16, wherein said bifunctional inhibitor molecule (I) is administered as a pharmaceutical preparation.

B, F & F Ref: STAN-166  
Stanford Ref: S99-205  
FADOCUMENT\STAN (Stanford)\166\response to advisory DCD